NEW YORK — Bionano Genomics said on Thursday that it has priced an $18 million public offering of stock and warrants.
The company also recently announced its participation in a project investigating the genetics of susceptibility to COVID-19.
Through the offering, the San Diego-based company will sell 54.5 million shares of its common stock — or prefunded warrants to purchase common stock in lieu thereof — along with warrants to purchase an additional 54.5 million common shares. Each share will be sold with one warrant for $.33.
For every prefunded warrant sold, the number of shares of common stock offered will be decreased on a one-to-one basis, Bionano said.
The offering is expected to close on or around April 6. Oppenheimer is acting as the sole book-running manager for the offering, with Roth Capital and Maxim Group acting as lead managers.
Earlier this week, Bionano said that its Saphyr Genome Imager for structural variation detection is being used in a large-scale study of COVID-19 susceptibility.
The study, being conducted at Hannover Medical School in Germany, aims to analyze the genomes of 1,000 COVID-19 and controls using next-generation sequencing and the Saphyr system in order to identify genomic variants that affect the disease, as well as immune or metabolic variables that may protect against severe disease, Bionano said.
The company added that it is donating the consumables needed for structural variant analysis to the study as part of the Tech Against COVID initiative recently launched by Rescale, Google, and Microsoft to donate high performance computing resources to teams working on COVID-19 tests and vaccines.